

Prescriber Name:

Prescriber Address:

Oral Anti-Diabetic Medications

EXCEPTION DRUG STATUS (EDS) REQUEST FORM

Fax: (204) 942-2030 or 1-877-208-3588

Fax Number:

Phone Number:

			Prescriber License Number (NOT Billing Number):		
Patient First Name:		PHIN:		MHSC:	
Patient Last Name:		Patient's Date of	Patient's Date of Birth:		
Medication Requested:					
Canagliflozin		Saxagliptin			
Empagliflozin		Sitagliptin			
Linagliptin					
Please note: for combina the generic EDS applicat	ation products (ex. Empagliflozin/me tion found at <u>https://www.gov.mb.ca</u>	etformin, sitagliptin /health/pharmaca	n/metformin, saxagliptin/me re/profdocs/eds_reqform.p	etformin), please use o <u>df</u>	е
Requested Strength and Re	egimen:				
https://www.gov.mb.ca/l	common drugs requested under the alth/mdbif/docs/edsnotice.pdf	the EDS Program	n can be found here:		
For INITIAL Requests:	Type 2 Diabetes				
Diagnosis/Indication:	Adjunct to diet, exercise and standard of care therapy to reduce the incidence of cardiovascular (CV) death in patients with type 2 diabetes mellitus (for empagliflozin only)				
	Other:				
Please check YES or N	O to all of the following statemen	ts:			
Patient has had a trial of metformin which resulted in int		tolerance or inade	quate diabetes control.	YES	NO
Patient has had a trial of a sulfonylurea which resulted i		in intolerance or ir	nadequate diabetes control	I. YES	NO
Insulin is not an option for this patient.				YES	NO
If no to any of the abov	e statements, please provide ratio	onale:			

History of myocardial infarction (MI).				
Multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status).				
Single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection.				
Last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease.				
History of ischemic or hemorrhagic stroke.				
Occlusive peripheral artery disease.				
Additional Relevant Clinical Information:				
Prescriber Signature and Date:				
Please check the following:				

I have discussed with the patient that the purpose of releasing their information to Manitoba Health, Seniors and Long-Term

Prescriber Signature:

Care is to obtain Exception Drug Status for prescription coverage.

Date:

Patient has established cardiovascular disease defined as one of the following (for empagliflozin only):

Updated March 17, 2025